State of Alaska Department of Revenue Buys 4,267 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

State of Alaska Department of Revenue lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 13.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 36,005 shares of the biopharmaceutical company’s stock after acquiring an additional 4,267 shares during the quarter. State of Alaska Department of Revenue’s holdings in Regeneron Pharmaceuticals were worth $25,976,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. MADDEN SECURITIES Corp bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $26,000. Ronald Blue Trust Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 157.9% during the third quarter. Ronald Blue Trust Inc. now owns 49 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 30 shares in the last quarter. SeaCrest Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $40,000. MinichMacGregor Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $53,000. Finally, Carolinas Wealth Consulting LLC raised its holdings in shares of Regeneron Pharmaceuticals by 39.3% during the third quarter. Carolinas Wealth Consulting LLC now owns 78 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 22 shares in the last quarter. Institutional investors own 84.25% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock traded down $2.10 during trading on Friday, hitting $747.65. 893,629 shares of the company’s stock traded hands, compared to its average volume of 538,123. The company has a debt-to-equity ratio of 0.12, a current ratio of 5.06 and a quick ratio of 4.29. Regeneron Pharmaceuticals, Inc. has a 1 year low of $538.01 and a 1 year high of $800.48. The stock has a market capitalization of $81.74 billion, a P/E ratio of 19.55, a PEG ratio of 2.58 and a beta of 0.21. The business has a 50-day simple moving average of $746.63 and a 200-day simple moving average of $729.64.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) last released its quarterly earnings data on Friday, February 3rd. The biopharmaceutical company reported $12.56 EPS for the quarter, beating the consensus estimate of $8.18 by $4.38. Regeneron Pharmaceuticals had a return on equity of 22.87% and a net margin of 35.64%. The company had revenue of $3.41 billion for the quarter, compared to analysts’ expectations of $3.11 billion. During the same period last year, the firm posted $23.72 earnings per share. Regeneron Pharmaceuticals’s revenue was down 31.1% compared to the same quarter last year. As a group, analysts forecast that Regeneron Pharmaceuticals, Inc. will post 34.22 EPS for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, insider George Yancopoulos sold 13,189 shares of the stock in a transaction dated Monday, February 6th. The stock was sold at an average price of $800.08, for a total value of $10,552,255.12. Following the transaction, the insider now owns 200,504 shares of the company’s stock, valued at $160,419,240.32. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other Regeneron Pharmaceuticals news, insider George Yancopoulos sold 13,189 shares of the stock in a transaction dated Monday, February 6th. The stock was sold at an average price of $800.08, for a total value of $10,552,255.12. Following the transaction, the insider now owns 200,504 shares of the company’s stock, valued at $160,419,240.32. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director N Anthony Coles sold 5,758 shares of the stock in a transaction dated Wednesday, December 28th. The shares were sold at an average price of $714.11, for a total value of $4,111,845.38. Following the completion of the transaction, the director now directly owns 1,093 shares in the company, valued at approximately $780,522.23. The disclosure for this sale can be found here. Insiders have sold 27,273 shares of company stock valued at $21,189,979 over the last ninety days. Insiders own 8.99% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on REGN shares. Cowen upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the company from $775.00 to $875.00 in a report on Monday, January 30th. BMO Capital Markets upped their price target on Regeneron Pharmaceuticals from $1,001.00 to $1,025.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 14th. SVB Leerink upped their price target on Regeneron Pharmaceuticals from $770.00 to $834.00 and gave the stock a “market perform” rating in a research note on Monday, February 6th. Morgan Stanley upped their price target on Regeneron Pharmaceuticals from $868.00 to $873.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 24th. Finally, Royal Bank of Canada upped their price target on Regeneron Pharmaceuticals from $787.00 to $806.00 and gave the stock a “sector perform” rating in a research note on Thursday, March 9th. One analyst has rated the stock with a sell rating, four have given a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $815.38.

Regeneron Pharmaceuticals Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.